Early evaluation of targeted therapy effectiveness in non-small cell lung cancer by dynamic contrast-enhanced CT

详细信息    查看全文

• 作者：P.-G. Qiao ; H.-T. Zhang ; J. Zhou ; M. Li ; J.-L. Ma…
• 关键词：Non ; small cell lung cancer ; Targeted therapy ; Dynamic contrast ; enhanced computed tomography ; Efficacy evaluation
• 刊名：Clinical and Translational Oncology
• 出版年：2016
• 出版时间：January 2016
• 年：2016
• 卷：18
• 期：1
• 页码：47-57
• 全文大小：6,626 KB
• 参考文献：1.Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96.PubMed CrossRef
  2.Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med. 2002;346:92–8.PubMed CrossRef
  3.Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small cell lung cancer: results from a randomized, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet. 2005;366:1527–37.PubMed CrossRef
  4.Satouchi M, Negoro S, Funada Y, Urata Y, Shimada T, Yoshimura S, et al. Predictive factors associated with prolonged survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib. Br J Cancer. 2007;96:1191–6.PubMed PubMedCentral CrossRef
  5.Scagliotti G, Govindan R. Targeting angiogenesis with multitargeted tyrosine kinase inhibitors in the treatment of non-small cell lung cancer. Oncologist. 2010;15:436–46.PubMed PubMedCentral CrossRef
  6.Zhao B, James LP, Moskowitz CS, Guo P, Ginsberg MS, Lefkowitz RA, et al. Evaluating variability in tumor measurements from same-day repeat CT scans of patients with non-small cell lung cancer. Radiology. 2009;252:263–72.PubMed PubMedCentral CrossRef
  7.Colombi D, Di Lauro E, Silva M, Manna C, Rossi C, De Filippo M, et al. Non-small cell lung cancer after surgery and chemoradiotherapy: follow-up and response assessment. Diagn Interv Radiol. 2013;19:447–56.PubMed
  8.Fraioli F, Anzidei M, Zaccagna F, Mennini ML, Serra G, Gori B, et al. Whole-tumor perfusion CT in patients with advanced lung adenocarcinoma treated with conventional and antiangiogenic chemotherapy: initial experience. Radiology. 2011;259:574–82.PubMed CrossRef
  9.Liu-Jarin X, Stoopler MB, Raftopoulos H, Ginsburg M, Gorenstein L, Borczuk AC. Histologic assessment of non-small cell lung carcinoma after neoadjuvant therapy. Mod Pathol. 2003;16:1102–8.PubMed CrossRef
  10.Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50:122S–50S.PubMed PubMedCentral CrossRef
  11.Ng QS, Goh V, Fichte H, Klotz E, Fernie P, Saunders MI, et al. Lung cancer perfusion at multi-detector row CT: reproducibility of whole tumor quantitative measurements. Radiology. 2006;239:547–53.PubMed CrossRef
  12.Wang J, Wu N, Cham MD, Song Y. Tumor response in patients with advanced non–small cell lung cancer: perfusion ct evaluation of chemotherapy and radiation therapy. AJR Am J Roentgenol. 2009;193:1090–6.PubMed CrossRef
  13.Lind JS, Meijerink MR, Dingemans AM, van Kuijk C, Ollers MC, de Ruysscher D, et al. Dynamic contrast-enhanced CT in patients treated with sorafenib and erlotinib for non-small cell lung cancer: a new method of monitoring treatment? Eur Radiol. 2010;20:2890–8.PubMed PubMedCentral CrossRef
  14.Erasmus JJ, Gladish GW, Roemeling L, Sabloff BS, Truong MT, Herbst RS, et al. Inter-observer and intra-observer variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response. J Clin Oncol. 2003;21:2574–82.PubMed CrossRef
  15.Zhou Q, Zhang XC, Chen ZH, Yin XL, Yang JJ, Xu CR, et al. Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer. J Clin Oncol. 2011;29:3316–21.PubMed CrossRef
  16.Yabuuchi H, Hatakenaka M, Takayama K, Matsuo Y, Sunami S, Kamitani T, et al. Non-small cell lung cancer: detection of early response to chemotherapy by using contrast-enhanced dynamic and diffusion-weighted MR imaging. Radiology. 2011;261:598–604.PubMed CrossRef
  17.Usmanij EA, de Geus-Oei LF, Troost EG, Peters-Bax L, van der Heijden EH, Kaanders JH, et al. 18F-FDG PET early response evaluation of locally advanced non-small cell lung cancer treated with concomitant chemoradiotherapy. J Nucl Med. 2013;54:1528–34.PubMed CrossRef
  18.Lu S, Li ZM. Targeted therapy of lung cancer-data from Asia. China Oncology. 2007;17:8–13.
  19.Tacelli N, Santangelo T, Scherpereel A, Duhamel A, Deken V, Klotz E, et al. Perfusion CT allows prediction of therapy response in non-small cell lung cancer treated with conventional and anti-angiogenic chemotherapy. Eur Radiol. 2013;23:2127–36.PubMed CrossRef
  20.Tognolini A, Schor-Bardach R, Pianykh OS, Wilcox CJ, Raptopoulos V, Goldberg SN. Body tumor CT perfusion protocols: optimization of acquisition scan parameters in a rat tumor model. Radiology. 2009;251:712–20.PubMed PubMedCentral CrossRef
  21.Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307:58–62.PubMed CrossRef
  
• 作者单位：P.-G. Qiao (1)
  H.-T. Zhang (1)
  J. Zhou (1)
  M. Li (1)
  J.-L. Ma (1)
  N. Tian (1)
  X.-D. Xing (1)
  G.-J. Li (1)
  
  1. Department of Radiology, Affiliated Hospital of Academy of Military Medical Sciences, #8 Fengtai dong street, Fengtai District, Beijing, 100071, China
  
• 刊物主题：Oncology;
• 出版者：Springer Milan
• ISSN：1699-3055

文摘

Purpose To study the feasibility and clinical value of dynamic contrast-enhanced (DCE) computed tomography (CT) for early evaluation of targeted therapy efficacy in non-small cell lung cancer (NSCLC).